By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Progenics Pharmaceuticals, Inc. 

777 Old Saw Mill River Road

Tarrytown  New York  10591  U.S.A.
Phone: 914-789-2800 Fax: 914-789-2817


SEARCH JOBS

Progenics Pharmaceuticals, Inc., of Tarrytown, NY is a biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Principal programs are directed toward symptom management and supportive care and the treatment of HIV infection and cancer. The Company has four product candidates in clinical development and several others in preclinical development.

The Company, in collaboration with Wyeth, is developing methylnaltrexone for the treatment of opioid-induced side effects, including constipation and post-operative bowel dysfunction. In the area of HIV infection, the Company is developing the viral-entry inhibitor PRO 140, a humanized monoclonal antibody targeting the HIV coreceptor CCR5 (in phase 1b studies). In addition, the Company is conducting research on ProVax, a novel prophylactic HIV vaccine. The Company is developing in vivo immuno-therapies for prostate cancer, including a human monoclonal antibody-drug conjugate directed against prostate-specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells. Progenics is also developing vaccines designed to stimulate an immune response to PSMA. A recombinant PSMA vaccine is in phase 1 clinical testing. The Company is also developing a cancer vaccine, GMK, in phase 3 clinical trials for the treatment of malignant melanoma.

Last Updated: 06-09-2006

Key Statistics


Email: info@progenics.com
Ownership: Public

Web Site: Progenics Pharmaceuticals, Inc.
Employees:
Symbol: PGNX
 









Company News
Progenics Pharmaceuticals, Inc. (PGNX) Holds Conference Call This Morning On FDA Appeal Response Regarding Relistor® sNDA For Patients With Chronic Non-Cancer Pain 7/14/2014 6:07:51 AM
Progenics Pharmaceuticals, Inc. (PGNX) Schedules Investor Conference Call Following FDA Advisory Committee 6/13/2014 8:05:04 AM
Progenics Pharmaceuticals, Inc. (PGNX) Stock Trading Halted Today; FDA Advisory Committee To Consider And Provide Recommendations Regarding Peripherally-Acting Opioid Receptor Antagonists 6/11/2014 7:12:29 AM
Progenics Pharmaceuticals, Inc. (PGNX) CEO Mark Baker To Present At Jefferies and Co. Global Healthcare Conference 6/2/2014 4:50:52 PM
Progenics Pharmaceuticals, Inc. (PGNX)' PSMA ADC Data Selected For Poster Highlight Presentation At American Society of Clinical Oncology 2014 5/30/2014 8:27:42 AM
Progenics Pharmaceuticals, Inc. (PGNX) Announces First Quarter 2014 Financial Results 5/9/2014 9:08:50 AM
Progenics Pharmaceuticals, Inc. (PGNX) Sets First Quarter 2014 Financial Results Call For May 9 5/1/2014 9:06:33 AM
Progenics Pharmaceuticals, Inc. (PGNX) Announces The Completion Of Enrollment Of Chemotherapy Naive Cohort In Phase 2 Trial Of PSMA ADC 4/24/2014 8:54:58 AM
Salix Pharmaceuticals, Ltd. (SLXP) And Progenics Pharmaceuticals, Inc. (PGNX) Announce The Acceptance Of Submission To Expand The Use Of RELISTOR In Chronic Non-Cancer Pain By European Medicines Agency 4/22/2014 7:53:20 AM
Progenics Pharmaceuticals, Inc. (PGNX) CEO, Mark R. Baker, To Present At 13th Annual Needham Healthcare Conference 4/8/2014 7:50:34 AM
12345678910...
//-->